Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 28;21(23):9064.
doi: 10.3390/ijms21239064.

Emerging Modes of Treatment of IgA Nephropathy

Dita Maixnerova  1 , Vladimir Tesar  1
Affiliations
Review

Emerging Modes of Treatment of IgA Nephropathy

Dita Maixnerova et al. Int J Mol Sci. .

Abstract

IgA nephropathy is the most common primary glomerulonephritis with potentially serious outcome leading to end stage renal disease in 30 to 50% of patients within 20 to 30 years. Renal biopsy, which might be associated with risks of complications (bleeding and others), still remains the only reliable diagnostic tool for IgA nephropathy. Therefore, the search for non-invasive diagnostic and prognostic markers for detection of subclinical types of IgA nephropathy, evaluation of disease activity, and assessment of treatment effectiveness, is of utmost importance. In this review, we summarize treatment options for patients with IgA nephropathy including the drugs currently under evaluation in randomized control trials. An early initiation of immunosupressive regimens in patients with IgA nephropathy at risk of progression should result in the slowing down of the progression of renal function to end stage renal disease.

Keywords: ACEI; CKD; IgAN; corticosteroids; progression; proteinuria.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the result.

Figures

Figure 1
Figure 1
Therapeutic options related to the different targets. Target 1 (Hit 1): B-lymphocyte activation results in the production of Gd-IgA1 (IgA1 poorly O-glycosylated at the hinge region). Hit 2: B-cell production of anti-Gd-IgA (IgG). Inhibitors of BAFF/APRIL:Atacicept, blisibimod; Spleen tyrosine kinase inhibitor: Fostamatinib;Gut mucosa modulation: budesonide; Proteosome inhibitor: bortezomib, microbiome modulation (may modulate B-lymphocyte activity with the reduction of Gd-IgA1). Hit 3: IgA1 specific protease. Hit 4:Spleen tyrosine kinase inhibitor:Fostamatinib; Corticosteroids: Acthar/Prednisolone, Complement mediation:Avacopan (C5a), OMS721 (Lectin pathway), LNP023 (Alternative pathway); IgA1 specific protease; Sparsentan; Dapagliflozin.
See this image and copyright information in PMC

References

    1. Moriyama T., Tanaka K., Iwasaki C., Oshima Y., Ochi A., Kataoka H., Itabashi M., Takei T., Uchida K., Nitta K. Prognosis in IgA nephropathy: 30-year analysis of 1012 patients at a single center in Japan. PLoS ONE. 2014;9:e91756. doi: 10.1371/journal.pone.0091756. - DOI - PMC - PubMed
    1. Wyatt R.J., Julian B.A. IgA nephropathy. N. Engl. J. Med. 2013;368:2402–2414. doi: 10.1056/NEJMra1206793. - DOI - PubMed
    1. Cattran D.C., Coppo R., Cook H.T., Feehally J., Roberts I.S., Troyanov S., Alpers C.E., Amore A., Barratt J., Berthoux F., et al. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–545. doi: 10.1038/ki.2009.243. - DOI - PubMed
    1. Coppo R., Troyanov S., Camilla R., Hogg R.J., Cattran D.C., Cook T.H., Feehally J., Roberts I.S.D., Amore A., Alpers C.E., et al. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int. 2010;77:921–927. doi: 10.1038/ki.2010.43. - DOI - PubMed
    1. Reich H.N., Troyanov S., Scholey J.W., Cattran D.C., Toronto Glomerulonephritis Registry Remission of proteinuria improves prognosis in IgA nephropathy. J. Am. Soc. Nephrol. 2007;18:3177–3183. doi: 10.1681/ASN.2007050526. - DOI - PubMed

LinkOut - more resources